ENGENE Stock Surges 54.9% on $138M SPAC Deal and EG-70 Trial Catalyst

Introduction

ENGENE HOLDINGS INC (NASDAQ: ENGN; name_ko: 엔진 홀딩스) is a clinical-stage biotechnology company focused on developing non-viral genetic medicines. As of November 11, 2025, its share price is $9.31, reflecting a one-day gain of 54.91%, on a trading volume of 5,508,075 shares on the NASDAQ exchange.

Corporate Structure

Founded in 1999, ENGENE HOLDINGS INC is headquartered in Boston, Massachusetts, with a subsidiary, enGene Inc., located in Canada. The company employs between 11 and 50 staff members, according to LinkedIn data. Jason Hanson serves as Chief Executive Officer, and Hussein Sweiti, MD, MSc, was appointed Chief Medical Officer in 2025. The organization has partnerships with life sciences venture funds, including Forbion, BVF Partners, and Vivo Capital.

Gene therapy by Sangharsh Lohakare

Recent Developments and News

On November 1, 2023, ENGENE completed a business combination with Forbion European Acquisition Corp., securing gross proceeds of $138.0 million. These funds are intended to support its lead program, EG-70 (detalimogene voraplasmid), which is in a pivotal trial for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Patient enrollment for EG-70 is ongoing, with interim data from the pivotal study anticipated in mid-2024.

LinkedIn updates indicate that preliminary findings from the LEGEND trial pivotal cohort of detalimogene have reported improved complete response rates in NMIBC patients. The company plans to submit a Biologics License Application (BLA) in the second half of 2026.

In regulatory filings, ENGENE submitted a Form 8-K on September 30, 2025, disclosing Regulation FD communications, and on October 2, 2025, filed an amended Form 8-K under Item 5.02 relating to changes in its board or executive officers.

Financial and Strategic Analysis

The $138.0 million raised through the SPAC transaction and concurrent private financing is expected to provide capital for advancing EG-70 and expanding pipeline efforts in gynecological/genitourinary malignancies and respiratory diseases. The intraday share price increase of 54.91% reflects market attention to the company's activities. The company's strategy aims to integrate non-viral gene therapy into standard clinical practice through locally delivered treatments, focusing on reducing patient burden and improving therapeutic outcomes. Upcoming milestones include interim results from pivotal trials in mid-2024 and a BLA submission in H2 2026.

Market Position and Industry Context

ENGN operates within the biotechnology research sector, concentrating on gene-based immunotherapy for urology and oncology indications. Its lead program targets an unmet need in NMIBC, where established treatments, such as intravesical BCG and anti-PD-1/PD-L1 agents, present limitations in efficacy. The non-viral delivery platform positions ENGENE among a limited number of developers focusing on genetic medicines for mucosal tissues. Collaboration with community oncologists and urology specialists supports ENGENE's efforts to promote the adoption of its technology.

tl;dr

ENGENE HOLDINGS INC share price rose 54.91% to $9.31 on November 11, 2025, amid continued enrollment in its EG-70 pivotal trial for BCG-unresponsive NMIBC. The company completed a $138 million SPAC merger on November 1, 2023, and expects interim data in mid-2024. Preliminary LEGEND trial results support a planned BLA submission in H2 2026. Recent Form 8-K filings on September 30 and October 2, 2025, cover Regulation FD disclosures and executive changes. The company’s non-viral gene therapy platform is a central focus of its strategic initiatives.